The relationship between Helicobacter pylori seropositivity and COPD

Thorax

Volumn 70, Issue 10, 2015, Pages 923-929

  Sze, Marc A ^a   Roy Chen, Yu Wei ^a   Tam, Sheena ^a   Tashkin, Donald ^b   Wise, Robert A ^c   Connett, John E ^d   Man, SF Paul ^a   Sin, Don D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN G ANTIBODY; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTIBODY TITER; ARTICLE; BODY HEIGHT; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; FORCED EXPIRATORY VOLUME; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; INCOME; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOCIAL STATUS; BLOOD; COHORT ANALYSIS; COMPLICATION; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; ANTIBODIES, BACTERIAL; COHORT STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84942155634     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207059     Document Type: Article

References (34)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
2. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-53.
3. Ichinohe T, Pang IK, Kumamoto Y, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 2011;108:5354-9.
4. Russell SL, Gold MJ, Hartmann M, et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012;13:440-7.
5. Baty F, Putora PM, Isenring B, et al. Comorbidities and burden of COPD: a population based case-control study. PLoS One 2013;8:e63285.
6. Gencer M, Ceylan E, Yildiz Zeyrek F, et al. Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease and its relation to pulmonary function tests. Respiration 2007;74:170-5.
7. Siva R, Birring SS, Berry M, et al. Peptic ulceration, Helicobacter pylori seropositivity and chronic obstructive pulmonary disease. Respirology 2013;18:728-31.
8. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9.
9. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505.
10. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9.
11. Perry E, Francis B. The social class gap for educational achievement: a review of the literature. RSA Projects, 2010. https://www.thersa.org/discover/publications-andarticles/reports/the-social-class-gap-for-educational-achievement-a-review-of-theliterature/Download(accessed 23 Apr 2015).
12. Bach PB, Guadagnoli E, Schrag D, et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 2002;40(8 Suppl):IV-19--25.
13. Hepper NG, Fowler WS, Helmholz HF Jr. Relationship of height to lung volume in healthy men. Dis Chest 1960;37:314-20.
14. Jedrychowski W, Ksiezyk M. Indices of ventilatory lung function (FVC, FEV1, FEV %) which adjust for age and height. Br J Prev Soc Med 1973;27:121-5.
15. Gulcan M, Ozen A, Karatepe HO, et al. Impact of H. pylori on growth: is the infection or mucosal disease related to growth impairment? Dig Dis Sci 2010;55:2878-86.
16. Moayyedi P, Forman D, Duffett S, et al. Association between Helicobacter pylori infection and adult height. Eur J Epidemiol 2005;20:455-65.
17. Yang YJ, Sheu BS, Yang HB, et al. Eradication of Helicobacter pylori increases childhood growth and serum acylated ghrelin levels. World J Gastroenterol 2012;18:2674-81.
18. Nakagawa H, Tamura T, Mitsuda Y, et al. Significant association between serum interleukin-6 and Helicobacter pylori antibody levels among H. pylori-positive Japanese adults. Mediators Inflamm 2013;2013:142358.
19. Liu J, Wang F, Shi S. Helicobacter pylori infection increase the risk of myocardial infarction: a meta-analysis of 26 studies involving more than 20,000 participants. Helicobacter 2015;20:176-83.
20. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437-9.
21. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-92.
22. Etukudo OM, Ikpeme EE, Ekanem EE. Seroepidemiology of Helicobacter pylori infection among children seen in a tertiary hospital in Uyo, southern Nigeria. Pan Afr Med J 2012;12:39.
23. Malcolm CA, MacKay WG, Shepherd A, et al. Helicobacter pylori in children is strongly associated with poverty. Scott Med J 2004;49:136-8.
24. Fiedorek SC, Malaty HM, Evans DL, et al. Factors influencing the epidemiology of Helicobacter pylori infection in children. Pediatrics 1991;88:578-82.
25. Vonkeman HE, Deleest H, van Delaar M, et al. Assessment of Helicobacter pylori eradication in patients on NSAID treatment. BMC Gastroenterol 2012;12:133.
26. Kato S, Furuyama N, Ozawa K, et al. Long-term follow-up study of serum immunoglobulin G and immunoglobulin A antibodies after Helicobacter pylori eradication. Pediatrics 1999;104:e22.
27. Feldman M, Cryer B, Lee E, et al. Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA 1998;280:363-5.
28. Lopes D, Nunes C, Martins MC, et al. Eradication of Helicobacter pylori: past, present and future. J Control Release 2014;189:169-86.
29. Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989;321:1562-6.
30. Pietroiusti A, Diomedi M, Silvestrini M, et al. Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation 2002;106:580-4.
31. Mayr M, Kiechl S, Mendall MA, et al. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke 2003;34:610-15.
32. Chen Y, Segers S, Blaser MJ. Association between Helicobacter pylori and mortality in the NHANES III study. Gut 2013;62:1262-9.
33. Ikeda A, Iso H, Sasazuki S, et al. The combination of Helicobacter pylori- and cytotoxin-associated gene-A seropositivity in relation to the risk of myocardial infarction in middle-aged Japanese: The Japan Public Health Center-based study. Atherosclerosis 2013;230:67-72.
34. Schottker B, Adamu MA, Weck MN, et al. Helicobacter pylori infection, chronic atrophic gastritis and major cardiovascular events: a population-based cohort study. Atherosclerosis 2012;220:569-74.